Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 20, Pages -Publisher
MDPI
DOI: 10.3390/ijms232012326
Keywords
candesartan; PPAR gamma; placenta; trophoblast; first-trimester pregnancy; rosiglitazone; teratogenic; angiotensin II
Funding
- Austrian Science Fund (FWF) [P 33554, I 3304, 31-B26]
- Oesterreichische Nationalbank (Austrian Central Bank, Anniversary Fund) [18175]
- German Society for Prenatal Medicine (DGPGM)
Ask authors/readers for more resources
This study investigated the effects of candesartan on trophoblastic PPAR gamma and its target genes in early gestation. The results showed that candesartan did not negatively affect PPAR gamma or its target genes in human trophoblasts, but may influence angiogenesis in the placenta.
Angiotensin II receptor 1 blockers are commonly used to treat hypertension in women of childbearing age. While the fetotoxic effects of these drugs in the second and third trimesters of pregnancy are well documented, their possible impacts on placenta development in early gestation are unknown. Candesartan, a member of this group, also acts as a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, a key regulator shown to be important for placental development. We have previously shown that trophoblasts do not express the candesartan target-receptor angiotensin II type 1 receptor AGTR1. This study investigated the possible role of candesartan on trophoblastic PPAR gamma and its hallmark target genes in early gestation. Candesartan did not affect the PPAR gamma protein expression or nuclear translocation of PPAR gamma. To mimic extravillous trophoblasts (EVTs) and cytotrophoblast/syncytiotrophoblast (CTB/SCT) responses to candesartan, we used trophoblast cell models BeWo (for CTB/SCT) and SGHPL-4 (EVT) cells as well as placental explants. In vitro, the RT-qPCR analysis showed no effect of candesartan treatment on PPAR gamma target genes in BeWo or SGHPL-4 cells. Treatment with positive control rosiglitazone, another PPAR gamma agonist, led to decreased expressions of LEP and PPARG1 in BeWo cells and an increased expression of PPARG1 in SGHPL-4 cells. Our previous data showed early gestation-placental AGTR1 expression in fetal myofibroblasts only. In a CAM assay, AGTR1 was stimulated with angiotensin II and showed increased on-plant vessel outgrowth. These results suggest candesartan does not negatively affect PPAR gamma or its target genes in human trophoblasts. More likely, candesartan from maternal serum may first act on fetal-placental AGTR1 and influence angiogenesis in the placenta, warranting further research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available